Skip to main content

Part of the book series: NATO ASI Series ((ASIH,volume 90))

Abstract

The discovery and development of therapeutic agents for the treatment of human diseases involve a long and complex process (Table I). Through coordinated efforts, researchers with diverse scientific disciplines work together as a team to solve many of the issues illustrated in Table 2. In the past, drug metabolism studies were only conducted to support safety assessment in animals and clinical pharmacology studies in humans in the development process. However, scientists in drug metabolism are now playing an increasingly important role in the design, discovery, and development of new therapeutic agents. The evolution of this approach is in part due to the tremendous progress in cytochrome P450 research and the better understanding of the role of each human cytochrome P450 in drug metabolism and drug-induced toxicity. In fact, much of the knowledge regarding human and animal cytochrome P450s can now be either directly or indirectly applied to many aspects of the drug discovery and development process.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Botsch SB, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK, (1993) Identification and characterization of the cytochrome P450 enzymes involved in N- dealkylation of propafenone:molecular base for interaction potential and variable disposition of active metabolites. Mol. Pharmacol. 43: 120–126

    Google Scholar 

  • Correia MA, Ortiz de Montellano PR, (1992) Inhibitors of cytochrome P450 and possibilities for their therapeutic application, in Frontiers in Biotransformation, Volume 8, Ruckpaul K, Rein H, (eds). Akademie Verlag Berlin, p 74–144

    Google Scholar 

  • Gonzalez FJ, Crespi CL, Gelboin HV, (1991) cDNA-expressed human cytochrome P450s: A new age of molecular toxicology and human risk assessment. Mut. Res. 247: 113-127

    Google Scholar 

  • Guengerich FP, (1989) Characterization of human microsomal cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol. 29: 241–264

    Article  PubMed  CAS  Google Scholar 

  • Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR (1993) Terfenadine-ketoconazole interaction pharmacokinetic and electrocardiographic consequences. Jama 269: 1513–1518

    Article  PubMed  CAS  Google Scholar 

  • Humphrey MJ, Smith DA, (1992) Role of metabolism and pharmacokinetic studies in the discovery of new drugs - present and future perspectives. Xenobiotica 22: 743–755

    Article  PubMed  CAS  Google Scholar 

  • Lu AYH, Miwa GT, Wislocki PG, (1988) Toxicological significance of covalently bound drug residues. Rev. Biochem. Toxicol. 9: 1–27

    Google Scholar 

  • Marietta MA, (1993) Nitric oxide synthase structure and mechanism. J. Biol. Chem. 268: 12231–12234

    Google Scholar 

  • Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. Faseb J. 6: 752–758

    PubMed  CAS  Google Scholar 

  • Nathan C, (1992) Nitric oxide as a secretory product of mammalian cells. Faseb J. 6: 3051–3064

    PubMed  CAS  Google Scholar 

  • Spielberg SP, (1984) In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Federation Proc. 43: 2308–2313

    CAS  Google Scholar 

  • Van den Bossche H, (1992) Inhibitors of P450-dependent steroid biosynthesis: From research to medical treatment. J. Steroid Biochem. Molec. Biol. 43: 1003–1021

    Article  Google Scholar 

  • Walsh JS, Wang R, Bagan E, Wang CC, Wislocki PG, Miwa GT, (1987) Structural alterations that differentially affect the mutagenic and antitrichomonal activities of 5-nitroimidazoles. J. Med. Chem. 30: 150–156

    Google Scholar 

  • Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP, (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 290: 355–361

    Google Scholar 

  • Woosley RL, Chen Y, Freiman JP, Gillis RA (1993) Mechanism of the cardiotoxic actions of terfenadine. Jama 269: 1532–1536

    Article  PubMed  CAS  Google Scholar 

  • Wrighton SA, Stevens JC, (1992) The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicol. 22: 1–21

    Article  CAS  Google Scholar 

  • Yun CH, Okerholm RA, Guengerich FP, (1993), Oxidation of the antihistamine drug terfenadine in human liver microsomes-role of cytochrome P450 3A4 in N- dealkylation and C-hydroxylation. Drug Metab. Disp. 21: 403–409

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Lu, A.Y.H. (1995). Therapeutic Agents and Cytochrome P450. In: Arinç, E., Schenkman, J.B., Hodgson, E. (eds) Molecular Aspects of Oxidative Drug Metabolizing Enzymes. NATO ASI Series, vol 90. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79528-2_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79528-2_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-79530-5

  • Online ISBN: 978-3-642-79528-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics